You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Identification of Serodiagnostic Epitopes for SARS-CoV-2, endemic HCoV?s and influenza virus

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: NCIRD

    ABSTRACT: A novel human coronavirus, which causes severe acute respiratory disease, now known as SARSCoV-2 emerged in December 2019. Infection with SARS-CoV-2 spread rapidly worldwide and on 11 March 2020 it was declared a pandemic by the World Health Organization. As of 4 September 2020, there are over 26 million confirmed cases of coronavirus infectious disease (COVID-19) caused by this new viru ...

    SBIR Phase I 2021 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Ultrasensitive Detection of Urine LAM for Point-of-Care Diagnosis of All Forms of Tuberculosis

    SBC: Fluxus, Inc.            Topic: CGH

    ABSTRACT: Tuberculosis (TB) remains one of the most challenging diseases with ten million new cases and two million deaths yearly, and severe problems due to underdiagnosis and inadequate testing. A point-of-care (PoC) test for all kinds of TB that is sensitive, quick, simple, and not sputum-based is urgently needed. The most promising avenue to accomplish this is an immunoassay based on the TB bi ...

    SBIR Phase I 2021 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. A Totally Synthetic Immunostimulator that Targets Toll-like Receptor 2 and NOD2: Toward Improved Influenza Vaccines

    SBC: TEICHOS LABORATORIES, LLC            Topic: NCIRD

    ABSTRACT: Teichos technology, amacromolecularplatformofpeptidoglycanbiologics(sPGN)producedbyproprietary chemoenzymatictotalsynthesis,offersimprovedinfluenzavaccinesthroughsignificantlyimprovedadjuvant performance. TL-001, a stimulatory sPGN, demonstrated adjuvant activity at low doses in standard laboratory vaccination model. We propose to evaluate TL-001 for its potential utility as an influenza ...

    SBIR Phase I 2021 Department of Health and Human ServicesCenters for Disease Control and Prevention
  4. ART Provider and Patient Resource to Improve Communication about Outcomes and Treatment (APRICOT)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: NCCDPHP

    ABSTRACT:Infertility affects an estimated 8-12% of reproductive-aged couples, leading many to seek assisted reproductive technologies (ART) treatments such as in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). Approximately 1.9% of infants born in the United States each year are conceived using ART. The Fertility Clinic Success Rate and ...

    SBIR Phase I 2021 Department of Health and Human ServicesCenters for Disease Control and Prevention
  5. Electrochemical Assay to Monitor Anti-TB Antibiotics

    SBC: GINER INC            Topic: CGH

    ABSTRACT: Tuberculosis (TB) is one of the top ten causes of death globally and is the second most powerful single infectious agent behind HIV/AIDS. While the incidence of TB continues to decrease every year, there has been a significant rise in drug resistant TB (DR-TB), with 10% of the cases developing into extensively drug resistant TB (XDR TB). The therapeutic outcome of these drug resistant TB ...

    SBIR Phase I 2021 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. Intracranial Pressure Assessment and Screening System for Viral or Bacterial Infections (IPASS-VorBI)

    SBC: VIVONICS INC            Topic: CBD192005

    Pathogens reach the subarachnoid space (SAS) through the blood-stream, or from contiguous sites, and penetrate the blood-brain barrier though complex molecular and cellular mechanisms [1, 2]. For example, meningitis causes an imbalance between the water content of the brain parenchyma, CSF volume and cerebral blood flow thus resulting in a net increase of ICP [3]. Cerebral edema caused by inflamma ...

    SBIR Phase II 2021 Department of DefenseOffice for Chemical and Biological Defense
  7. Optimization of a broad-spectrum Ebolavirus cell entry inhibitor chemical series as a countermeasure for parental and aerosol routes of infection

    SBC: ARISAN THERAPEUTICS INC            Topic: CBD192006

    Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa [1,2]. Outbreaks of EBOV in the Democratic Republic of the Congo (DRC) as well as the 2014-2016 outbreak in West Africa highlight the danger that these zoonotic viruses pose through mucosal routes of infection and secondary human t ...

    SBIR Phase II 2021 Department of DefenseOffice for Chemical and Biological Defense
  8. Increasing Interoperability of Brain Morphometrics Using FHIR

    SBC: CORTICOMETRICS LLC            Topic: NIBIB

    PROJECT SUMMARY With the rise of artificial intelligence (AI) algorithms in medicine, radiologists have new tools at their disposal to quantitatively assess imaging data. However, in order to unlock this potential, data needs to be shared easily and effectively between all parts of the health information technology (IT) system. The goal of this project is to reduce data access barriers by developi ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Discovery of 12/15-lipoxygenase inhibitors to suppress neuroinflammation and slow disease progression in Alzheimer's disease

    SBC: ACUREX BIOSCIENCES CORP            Topic: NIA

    Shrader, William D. Abstract: Alzheimerandapos;s disease (AD) is the largest unmet medical need in the US and the only major cause of death that cannot be prevented, cured, or slowed. Arviat Pharmaceuticals, Inc. is developing oral small-molecule inhibitors of the 12/15-lipoxygenase (12/15-LO) enzyme family to reduce microglia driven neuroinflammation and, thereby, slow progression of AD. Inhibiti ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women

    SBC: BONE HEALTH TECHNOLOGIES, INC.            Topic: R

    Abstract Approximately 43 million Americans suffer from osteopenia, a highly common skeletal condition defined by accelerated bone loss. If bone loss is not mitigated, patients become osteoporotic and are at increased risk of bone fractures, particularly of the hips and spine. Such fractures decrease independent living, shorten life, and increase morbidity. Clinical guidelines for treating osteope ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government